Theralase Technologies Inc. – Trademark Portfolio
Entity Type: 03
Theralase Technologies Inc. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 7 trademarks are registered and 2 are pending. Notable registered marks include RUVIDAR, RUTHERRIN, CELLSENSING, LIGHT SPEED HEALING, and PAIN RELIEF AT THE SPEED OF LIGHT. The owner is based in Toronto, ON.
41 Hollinger Road
Toronto, ON M4B 3G4 , CA
Showing of trademarks Trademarks
Trademark Classifications
Theralase Technologies Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Theralase Technologies Inc. have?
Theralase Technologies Inc. has 9 U.S. trademarks filed with the USPTO. Of these, 7 registered, 2 pending.
What trademark classes does Theralase Technologies Inc. file in?
Theralase Technologies Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Theralase Technologies Inc.'s most well-known trademarks?
Theralase Technologies Inc.'s registered trademark portfolio includes well-known marks such as RUVIDAR, RUTHERRIN, CELLSENSING, LIGHT SPEED HEALING, and PAIN RELIEF AT THE SPEED OF LIGHT. These are among 7 currently registered trademarks in the portfolio.
What is Theralase Technologies Inc.'s trademark registration success rate?
Theralase Technologies Inc. has a 100% trademark registration rate, with 7 out of 7 resolved applications resulting in successful registration. Currently, 2 applications are pending review.